The Response Evaluation Criteria In PSMA-imaging (RECIP) were proposed to evaluate treatment efficacy using PSMA-ligand PET in metastatic castration-resistant prostate cancer patients [79]. The gene discussed is FOLH1; the disease is prostate carcinoma.